<DOC>
	<DOCNO>NCT00273975</DOCNO>
	<brief_summary>Trial evaluate steady state pharmacokinetic parameter nevirapine 150mg/m2 nevirapine 4 7 mg/kg 4 week , efficacy safety dose administer 48 week antiretroviral drug naïve paediatric patient .</brief_summary>
	<brief_title>Trial Evaluate Steady State Pharmacokinetic Parameters , Efficacy Safety Nevirapine Antiretroviral Drug naïve Pediatric Patients</brief_title>
	<detailed_description>A randomised open label multi-centre trial evaluate pharmacokinetic , efficacy safety parameter nevirapine 150mg/m2 nevirapine 4 7mg/kg administer combination ZDV 3TC 48 week antiretroviral naive pediatric patient . Primary objective : To evaluate steady state pharmacokinetic parameter nevirapine 150mg/m2 antiretroviral drug naive pediatric patient . Secondary objective : To assess efficacy safety nevirapine 150 mg/m2 nevirapine 4/7mg/kg 24 48 week treatment Study Hypothesis : Evaluation recent pharmacokinetic data suggest dose base body surface area rather body weight might well therapeutic regimen achieve steady state plasma concentration . The goal study determine Nevirapine suspension dose 150 mg/m2 BID , follow two week lead-in 150 mg/m2 QD , produce plasma nevirapine steady state concentration 4 - 6 ? g/mL age group observe adult safety efficacy trial . Comparison ( ) : ACTG 245</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion : 1 . Male female patient 3 month 16 year age day 28 study . 2 . Evidence HIV1 infection 3 . Patients antiretroviral drug naive 4 . Plasma viral load detectable 5 . CD4 &gt; =50 cells/cc3 6 . Written inform permission 7 . Active assent give patient child capable understanding give information 8 . Reasonable probability completion trial Exclusion : 1 . Any significant disease , HIV 2 . Any acute illness within 2 week prior Day 0 3 . Patients require continue use inhibitor inducer P450 metabolic enzymes 4 . Patients require systematic treatment CYP3A4 substrates 5 . Patients malabsorption , severe chronic diarrhea 6 . Receipt cytotoxic therapy malignancy 7 . Current grade 3 4 clinical laboratory toxicity 8 . Pregnancy breastfeed 9 . Females childbearing potential use adequate contraception . allergy know drug hypersensitivity study drug intravenous drug abuse , alcohol substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>